Phase 3 N=185 Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Xerostomia · Depression · Hypertension
Primary: Dry Mouth Questionnaire (DMQ) — 3.4; 1.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy
Xerostomia
Primary: Change in Percentage of Time With CPAP (Continuous Positive Airway Pressure) Usage — -5.09; 11.67 percentage of time
N/A N=25 Exploratory Study on Effect of Whitening Agent With Emulsion Gel in Xerostomic Population
Xerostomia
Primary: Subjective Perception of Mouth Dryness — 6.92; 6.46; 4.21; 3.46 units on a scale — p=.45
Phase 1 N=20 Fluoride Retention in the Mouth of Older Adults
Hyposalivation
Primary: Fluoride Concentration in Dental Biofilm Fluid at Baseline — 0.24; 0.22 parts per million (ppm) of fluoride — p=0.8412
N/A N=15 Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
Dry Mouth
Primary: Change From Baseline in Saliva Production in ml. — 1.41; 3.93; 5.31; 10.34 ml — p=0.05
N/A N=39 Clinical Evaluation of Oral Rinse for Xerostomia
Xerostomia
Primary: Change in Dry Mouth Symptom by Visual Analog Scale at 14 Days From Baseline — 10.1; 11.6; 13.0 mm
Phase 4 N=100 Effect of Korean Red Ginseng (KRG) on Dry Mouth
Xerostomia
Primary: Visual Analogue Scale of Subjective Dry Mouth — 5.21; 5.03 cm — p=<0.05
N/A N=42 Clinical Evaluation of MucoPEG™ for Xerostomia
Dry Mouth · Xerostomia
Primary: Change in VAS for Mouth Dryness — -0.8; -0.7; -1.5; -0.4 score on a scale — p=<0.01
N/A N=137 Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water Control
Dry Mouth
Primary: Response to "Relieving the Discomfort of Dry Mouth" From the Modified PPAQ I 4- and 6-hours Post-use on Day 1 of Treatment — 2.51; 3.26; 3.43 score on a scale
Phase 2 N=19 Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients
Sialorrhea Secondary to Parkinson's Disease
Primary: Sialorrhea Visual Analogue Scale (VAS) — -0.55; -1.08; -1.53; -0.81 cm on VAS — p=0.6
N/A N=52 Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation
Sialorrhea
Primary: Difference in Salivary Flow Rate (ml/Min) Between Study Groups — .072; .003; NA ml/min
Phase 2 N=49 Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer
Head and Neck Cancer · Radiation Toxicity · Xerostomia
Primary: Number of Patients Scored as Having the Surgical Technique of Submandibular Salivary Gland Transfer Performed "Per Protocol" — 34 participants
N/A N=129 Blinded Dry Mouth Spray Crossover Study
Xerostomia · Head and Neck Cancer · Xerostomia Following Radiotherapy
Primary: Oral Dryness — 45.5; 46.6; 52.76; 54.1 units on a scale — p=<0.501
N/A N=100 Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
Xerostomia
Primary: Mean Response to the Question 1 'Relieving the Discomfort of Dry Mouth' in Product Performance and Attributes Questionnaire 3 (PPAQ3) at 120 Minutes(Mins) Post Treatment…
N/A N=53 Use of Two Dissolvable Therapeutics Under Removable Partial Dentures
Edentulous Jaw · Edentulous Mouth
Primary: Change From Baseline in Patient Comfort for as Assessed by Numerical Scale. — 0.99; 1.16 units on a scale
N/A N=15 Factors Controlling the Formation of Salivary Films
Healthy
Primary: Impact of Ingredients on Thickness (Depth, nm) of Salivary Films Adsorbed Onto Solid Surfaces — 27 nm
N/A N=396 A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
Xerostomia
Primary: Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1: Relieving the Discomfort of Dry Mouth) — 2.7; 2.9; 2.6; 2.0 Score on scale…
Phase 2 N=60 Green Tea Lozenges for the Management of Dry Mouth
Xerostomia · Sjogren Syndrome · Dry Mouth
Primary: Change in Salivary Flow From Baseline — 0.17; 0.10; 0.66; 0.04 ml/min
N/A N=40 Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray
Xerostomia
Primary: 10 cm Mouth Dryness Visual Analog Score — 4.51; 4.6 cm
Phase 3 N=187 Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Sialorrhea
Primary: Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A) — -0.37; -0.36; -0.07 g/minute — p=<0.0001
Phase 2 N=24 A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
Sialorrhoea
Primary: Saliva Secreted Rate — -6.508; -34.512; 83.695; 7.414 percentage of change from baseline
Phase 2 N=10 Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Sialorrhea
Primary: Objectively Measured Salivary Weight — -0.07; -0.68 gm
N/A N=16 Effects of an External Oral Irrigation Device on Patients With Dry Mouth
Xerostomia
Primary: Change in Oral Health Related Quality of Life (OHRQoL) — 10.2 score on a scale
Phase 2 N=30 Mesenchymal Stemcells for Radiation Induced Xerostomia
Xerostomia
Primary: Number of Participants With Adverse Events as a Measure of Safety — 0; 0 participants
Phase 2 N=104 Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome
Xerostomia · Sjogren's Syndrome
Primary: Overall Improvement Rate in Dry Mouth Symptoms — 26.0; 20.0; 44.0; 27.1 percentage of participants
N/A N=55 Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects
Xerostomia
Primary: Number of Participants With Response to Post-Product Use Questionnaires 1 (PPUQ 1); Question No.1 — 1; 1; 5; 0 Participants
N/A N=66 Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
KERATOCONJUNCTIVITIS SICCA · XEROSTOMIA · SICCA SYNDROME
Primary: The Xerostomia Inventory — 40.2; 39.3 units on a scale — p=0.05
Phase 3 N=196 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Xerostomia
Primary: Phase II: Treatment Compliance (Number of Compliant Patients) — 12; 44 Participants
N/A N=22 A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse
Dry Mouth
Primary: Product Performance and Attributes (PPAQ I) Question #1: 2-hr at Day 4 — 1.79; 2.97; 3.33 units on a scale
N/A N=29 Duration of Effect of Biotene Spray in Patients With Dry Mouth
Dry Mouth
Primary: Mean Duration of Action of Intervention — 27; 26 minutes